831
Views
35
CrossRef citations to date
0
Altmetric
Original Articles

THE SPECTROPHOTOMETRIC DETERMINATION OF CISPLATIN IN URINE, USING o-PHENYLENEDIAMINE AS DERIVATIZING AGENT

, , &
Pages 113-123 | Received 01 Sep 2000, Accepted 29 Sep 2000, Published online: 02 Feb 2007
 

Abstract

A visible spectrophotometric method has been developed for determination of the antitumour agent cis-diammindichloroplatinum (II) in urine. The method is based on the measurement of the absorbance of the reaction product of the drug and o-phenylenediamine. Optimum conditions of the reaction were established. The product was obtained at pH 6.2; in 30 min at 90°C, giving a maximum absorbance at 705 nm, which is far beyond the wavelengths of the absorption of cisplatin itself, o-phenylenediamine, and the biomolecules in urine. The chloride ion interference and the other possible interferences originated from the urine matrix were overcome by using the standard addition method and also the high concentration of the reactant. The drug could be detected and determined without any interference. The reaction product was stable in urine for 5 days at ambient temperature. The standard addition curve was linear in the concentration range of 0.42–3.16 μg/ml in respect to the final concentration of cisplatin. The detection limit of cisplatin in spiked urine samples was 8.40 μg/ml.

ACKNOWLEDGMENTS

The authors are grateful to Prof. Dr. Jan Reedijk from Leiden University, Leiden Institute of Chemistry, The Netherlands; Dr. Hermann Watzig, Ins. Fur Pharmazie und Lebensmittelchemie, Wurzburg, Germany; and Huriye Kuzu, Faculty of Science and Literature, Yildiz University, Istanbul, Turkey, for their careful reading of the manuscript and for useful suggestions. We would also like to thank Asta Medica, Franfurt am Main, Germany, for providing cisplatinum as a gift and Marmara University Research Fund, Istanbul, Turkey, and Onko Ecza Koçsel A., Turkey, for their financial support.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.